APPENDIX

PROSTATE GLAND: Systematic +/- Targeted Needle Biopsy

Specimen #:
Patient:
Part:
Initials/Date:

Procedure
Needle Biopsy
Specimen Site
Prostatic structure
Tumor Site

Histologic Type
Adenocarcinoma (acinar, not otherwise specified)
Other (specify) ______________

Gleason score/ WHO Grade of worst site/core (list location______):
Not applicable
Cannot be determined
WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
WHO Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10

Global Gleason score/WHO Grade, including systematic and targeted biopsies
WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
WHO Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10
Percent Gleason Patterns 4 and/or 5: ____%

Cribriform pattern:
Present
Not present
Indeterminable

Intraductal carcinoma:
Present
Not present
Indeterminable
Included in grade assignment

Tumour quantitation & Extent of carcinoma
Number of positive sites:
Total number of sites:
Number of positive cores:
Total number of cores:
Maximum carcinoma extent for Core with the Greatest Amount of Tumour (mm OR % involvement) ______
Maximum carcinoma extent (mm OR % involvement)_________________

Method of tumour measurement
Multiple foci counted as continuous core involvement
Multiple foci counted as discontinuous core involvement
Single continuous focus

**Perineural Invasion**
- Not identified
- Present

**Periprostatic Fat Invasion**
- Not identified
- Present
- Not applicable

**Seminal Vesicle Invasion***
- Not identified
- Present
- Not applicable

* SV involvement applicable only if intentional stage biopsy of same performed. The presence of SV/ejaculatory duct epithelium should be noted in report with comment that histology cannot differentiate between the two and correlation with imaging is recommended.

**Lympho-Vascular Invasion**
- Not identified
- Present
- Indeterminate

**Other features**
- HGPIN
- Adenosis
- ASAP
- Inflammation
- Other

**Systematic biopsies (excluding targeted biopsies)**
Aggregate Gleason score/WHO Grade
Composite Gleason score/WHO Grade (if applicable) of worst site
- Not applicable
- Cannot be determined
- WHO Grade 1: Gleason score 6
- WHO Grade 2: Gleason score 3+4=7
- WHO Grade 3: Gleason score 4+3=7
- WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
- WHO Grade 5: Gleason score 9-10
- Percent Gleason Patterns 4 and/or 5: ____%

**Cribiform pattern:**
- Present
- Not present
- Indeterminate

**Intraductal carcinoma:**
- Present
- Not present
- Indeterminate
- Included in grade assignment

**Tumour quantitation & Extent of carcinoma**
- Number of positive sites:
- Total number of sites:
Downes MR, et al. Target prostate biopsies: How best to report in synoptic format?

Number of Cores Positive _____
Total Number of Cores _____

Maximum carcinoma extent for Core with the Greatest Amount of Tumour (mm OR % involvement) _____
Maximum carcinoma extent (mm OR % involvement)

**Method of tumour measurement**
Multiple foci counted as continuous core involvement
Multiple foci counted as discontinuous core involvement
Single continuous focus

**Targeted lesions (list number and site of positive Targets)*

Not identified
Present

**Detected by**
DRE
Ultrasound
MRI
Other:
Location:

**Composite Gleason score/WHO Grade Target X**
Not applicable ______________
Cannot be determined ______________
WHO Grade 1: Gleason score 6
WHO Grade 2: Gleason score 3+4=7
WHO Grade 3: Gleason score 4+3=7
WHO Grade 4: Gleason score 4+4=8; 3+5=8; 5+3=8
WHO Grade 5: Gleason score 9-10
Percent Gleason Patterns 4 and/or 5: _____ %

**Cribiform pattern:**
Present
Not present
Indeterminate

**Intraductal carcinoma:**
Present
Not present
Indeterminate
**Included in grade assignment**

**Tumour quantitation & Extent of carcinoma**
Number of targeted cores positive _____
Total number of targeted cores _____

Aggregate measurement of carcinoma extent as mm involvement or percentage: _____ %
Maximum carcinoma extent for Core with the Greatest Amount of Tumour (mm OR % involvement) _____

**For Negative Target**
Benign histology (document same)

* Report each positive Target site separately- necessitates repeating this section per positive Target